Systemic treatment of renal cell cancer: A comprehensive review

•Treatment of RCC is rapidly evolving along with the uncovering of its molecular basis.•VEGFR, PDGFR along with mTOR represent critical targets in RCC therapeutics.•PD-1 and MET-AXL-VEGFR inhibition have now been confirmed as valid strategies.•The mechanisms of resistance and best treatment sequenci...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment reviews 2017-11, Vol.60, p.77-89
Main Authors: Sánchez-Gastaldo, Amparo, Kempf, Emmanuelle, González del Alba, Aránzazu, Duran, Ignacio
Format: Article
Language:English
Subjects:
Angiogenesis
Antineoplastic Agents - therapeutic use
Carcinoma, Renal Cell - drug therapy
Human health and pathology
Humans
Immunotherapy
Immunotherapy - methods
Kidney Neoplasms - drug therapy
Life Sciences
Molecular Targeted Therapy - methods
Monoclonal antibody
mTOR inhibitor
Renal cell cancer
Targeted therapy
Tyrosine-kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Treatment of RCC is rapidly evolving along with the uncovering of its molecular basis.•VEGFR, PDGFR along with mTOR represent critical targets in RCC therapeutics.•PD-1 and MET-AXL-VEGFR inhibition have now been confirmed as valid strategies.•The mechanisms of resistance and best treatment sequencing remain unanswered.•Results from combination/sequencing studies will probably define a paradigm change. Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2017.08.010